



City of Seattle Boards & Commissions Notice of Appointment

Appointee Name: <i>Kurt Lustig</i>		
Board/Commission Name: <i>Seattle Fire Code Advisory Board</i>		Position Title: <i>Labs/Research Representative</i>
<input type="checkbox"/> Appointment OR <input checked="" type="checkbox"/> Reappointment		Council Confirmation required? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Appointing Authority: <input type="checkbox"/> Council <input checked="" type="checkbox"/> Mayor <input type="checkbox"/> Other:	Date Appointed: 8/8/2019	Term of Position: * 6/1/2019 to 5/31/2022 <input type="checkbox"/> Serving remaining term of a vacant position
Residential Neighborhood: <i>Queen Anne</i>	Zip Code: <i>98119</i>	Contact Phone No.:
Background: <p>Mr. Lustig has more than 20 years of experience in the area of life sciences, biotechnology, and vivarium settings, including facility operation and design. He is currently the senior manager of preclinical Operations and Translational Pharmacology at Kineta, Inc. In this role he chairs the company's Environmental Health and Safety committee, the Institutional Biosafety committee, and is the point person for the National Institutes of Health (NIH), the DEA, and USDA/APHIS inspectors.</p> <p>In addition to his work in the biotechnology sector, Mr. Lustig volunteers at the ROOTS (Rising Out of the Shadows) Young Adult Shelter and is in the process of becoming a CASA (Court Appointed Special Advocate) volunteer.</p> <p>Seattle has a vibrant laboratory and biotechnology industry and effective representation for the sector is essential to the work of the Seattle Fire Code Advisory Board. Mr. Lustig's background, knowledge, and engagement make him an excellent candidate for the Research/Labs position.</p>		
Authorizing Signature (original signature): 		Appointing Signatory: <i>Jenny A. Durkan</i> <i>Mayor, City of Seattle</i>

FILED
 CITY OF SEATTLE
 19 AUG - 8 PM 2 16
 CITY CLERK

*Term begin and end date is fixed and tied to the position and not the appointment date.

Kurt Howell Lustig



Professional Experience

- 2017-Present *Associate Director; Preclinical Operations and Translational Pharmacology; Translational Pharmacology and Development, Kineta Inc., Seattle Washington*
- 2015-2017 *Senior Manager; Preclinical Operations and Translational Pharmacology; Translational Pharmacology and Development, Kineta Inc., Seattle Washington*
- 2013-2015 *Principal Research Associate / Vivarium Operations Manager; Translational Pharmacology and Development, Kineta Inc., Seattle Washington*

- Perform and/or manage IND-enabling pharmacokinetic, pharmacodynamic and toxicology studies for lead candidate small molecules in both non-human primate (NHP) and rodents and related assays to evaluate drug levels and biomarkers; Audit off-site CRO translational pharmacology studies
- Manage a team of research associates for the translational pharmacology and development group
- Assist and collaborate with other internal groups and programs to help facilitate carrying out in vivo studies and associated assays
- Develop models as well as design and perform POC in vivo studies for Kineta research programs
- Manage Kineta's Animal Facility and Institutional Animal Care and Use Committee (Chair); deliver animal use training sessions; Chair/manage Environmental Health and Safety for company; Chair/manage company Institutional Biosafety Committee; Group and team meeting presentations

2012-2013 *Associate Scientist, Preclinical Biology and In Vivo Pharmacology, VLST Corp., Seattle Washington*

2006-2011 *Senior Research Associate II, Preclinical Biology and In Vivo Pharmacology, VLST Corp., Seattle Washington*

- Evaluate biologic-based therapeutic candidates in numerous inflammation/autoimmune disease models including: CIA, CAIA, IDDM, EAE, SLE, IBD, EAMG, DTH, immune-complex peritonitis, airway hyperresponsiveness, acute lung injury, and other immunologically relevant models
- Develop and perform *ex vivo* assays including ELISA and Meso-Scale Discovery (MSD) based formats to evaluate and characterize biologic therapeutics such as fusion proteins and monoclonal antibodies
- Perform and/or manage pharmacokinetic, pharmacodynamic and toxicology studies for lead candidate biologics in both non-human primate (NHP) and rodent and carry out related assays to evaluate drug levels and biomarkers
- Manage/audit off-site CRO studies for Preclinical group; GLP / Non-GLP NHP and rodent
- Develop NHP model and train CRO personnel in specialized techniques
- Develop and maintain preclinical documents for IND-enabling studies including drafting protocols, study documentation, data analysis, and assistance in report writing
- Develop humanized mouse models (hu-NSG-PBL, xenogeneic GvHD) and initiate studies to assess human therapeutic potency in a murine/human chimera
- Carry out cloning and site-directed mutagenesis for affinity maturation of lead therapeutic candidates
- Other responsibilities include: Act as liaison for animal facility and VLST IACUC; deliver animal use training sessions, serve as Biological Safety Officer; manage health and safety issues within Preclinical group and animal facility; group and team meeting presentations

Kurt H. Lustig

- 2005-2006 *Research Consultant, Nastech Pharmaceutical Company Inc., Bothell Washington*
- Trained personnel in *in vivo* dosing and modeling techniques
 - Trained personnel in cellular and molecular biology techniques
 - Designed, established and initiated *ex vivo* studies to screen siRNA candidates for virus knock-down efficiency
 - Established BL2 protocols for Influenza A virus use in *in vivo* and *in vitro* settings
- 2001-2005 *Senior Research Associate, Targeted Genetics Corporation, Seattle Washington.*
- Developed models for both systemic and local delivery of gene therapy based products and initiated *in vivo* studies to assess efficacy and biodistribution of adeno-associated viral (AAV) RA and hemophilia A and hemophilia B therapeutics using mouse and rat models
 - Performed research for the characterization of *in vivo* gene expression (tissue-associated and secreted proteins) delivered by different AAV serotypes, following different routes of administration in rats and mice
 - Designed and initiated studies characterizing gene expression in conjunction with proteasome inhibiting, and absorption enhancing compounds; assessed the mechanism of action of the gene therapy based products in both *in vivo* and *in vitro* systems as means of better understanding and improving the current product
 - Managed off-site *in vivo* portion of academic projects at the University of Pennsylvania and University of Michigan; generated data from said projects and assessed efficacy in periodontal and atherosclerotic disease models
 - Coordinated and managed off-site transgenic mouse colony
 - Managed and supervised multiple lab and support personnel
- 2000-2001 *Research Associate, Northwest Biotherapeutics/Northwest Hospital Dept. of Molecular Medicine, Bothell Washington.*
- Developed and performed protocols for primary simian cell isolation and culture
 - Developed protocols for isolation and culture of simian B cells and dendritic cells for *ex vivo* therapies
 - Other responsibilities included: Setting up and training personnel for new BL2 suite at new biotechnology company, establishing safety and laboratory maintenance protocols; Maintained collaboration between Northwest Biotherapeutics and Northwest Hospital Dept. of Molecular Medicine
- 1998-2000 *Research Technologist II, University of Washington, Department of Pathobiology / Washington National Primate Research Center*
- Established protocols for peptide conjugation techniques, animal models for systemic and local induction of vaccine and assays to assess conjugation and vaccine potency
 - Designed, established and initiated *in vivo* studies using an anti-peptide mucosal immunity approach with HIV-1 peptides conjugated to Cholera Toxin and mutant heat-labile enterotoxin
 - Established modified BL2 animal procedures for group and used BL3 routinely for isolations of PBMC's from HIV and SIV infected blood
 - Generated large-scale preparations of vaccinia virus stocks
- 1993-1998 *Research Associate, University of South Dakota, Department of Anatomy and Structural Biology*
- Conducted research project comparing and mapping similarities and differences of the organizational features of mammalian and non-mammalian cortex and subcortical motor systems
 - Excised and prepared turtle and rat brains for intracellular cell filling and anterograde tract tracing; Performed retrograde injections of neurons in both mammalian and reptilian models
 - Established and initiated immunohistochemistry protocols for live and fixed cells and carried out data collection using photo microscopy utilizing SEM, confocal microscope and Nomarski optics

Kurt H. Lustig

- Performed research projects studying cardiac function relating to disease states, specifically myocyte shape and structure remodeling
- Designed, established and initiated studies utilizing enzymatic isolation of cardiac myocytes from chicken and turtle hearts. Developed techniques for collecting hemodynamic data using Millar catheter and ultrasound technology
- Performed NHP *in vivo* perfusions/fixations

Other training and skills

- Training in electron (TEM and SEM) and light microscopy including photomicrography
- BSL3 facility and modified BSL2 animal room training
- University certified programs of instruction: Principles of Radiation Protection, Blood borne Pathogen Exposure Control, Managing Laboratory Chemicals/Spill Clean-up, Animal Use Training Session-Mouse, Animal Use Training Session-Rat

Education

1994 Bachelor of Science, Psychology/ Chemistry minor
University of South Dakota, Vermillion

1995 Graduate studies in Structural Biology
University of South Dakota, Vermillion

Continuing education:

- Practical Toxicology Course in Drug Development, University of Wisconsin, 2008
- American Association of Immunologists, Basic Immunology Course, 2009
- Federation of Clinical Immunology Societies Annual Meeting, Vancouver, BC, 2012

Publications / Abstracts

P. Probst, R.A. Salmon, A. McNabb, M. Diegel, **K.H. Lustig**, A.R. Posey, S.R. Wiley, D.L. Bienvenue, A. Kaykas, C.A. Smith, T. M. Foy. Signal regulatory protein alpha as a novel therapeutic target for the treatment of Fcγ receptor-mediated inflammatory diseases. *Eur. J. Immunol.* Manuscript submitted, 2012.

M. L. Scalley-Kim, B. W. Hess, R.L. Kelly, A.R. Krostag, **K.H. Lustig**, J. S. Marken, P. J. Owendale, A.R. Posey, P. J. Smolak, J.D. Taylor, C.L. Wood, D. L. Bienvenue, P. Probst, R.A. Salmon, D.S. Allison, T.M. Foy, C.J. Raport. A novel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation. *PLoS One.* 7(8):e43332, 2012

J.A. Cirelli, C.H. Park, K. MacKool, M. Taba Jr, **K.H. Lustig**, H. Burstein and W.V. Giannobile. AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. *Gene Therapy.* 16, 426–436, 2009.

Z. Sandalon, E.M. Bruckheimer, **K.H. Lustig**, H. Burstein. Long-term Suppression of Experimental Arthritis Following Intramuscular Administration of a Pseudotyped AAV2/1-TNFR:Fc Vector. *Molecular Therapy.* 15, 264–269, 2007.

T. Stepan, Z. Sandalon, **K. Lustig**, H. Burstein. Improving the stability of Ad-AAV hybrid vectors. ASGT meeting 2006.

Z. Sandalon, **K. Lustig**, H. Burstein. Suppression of Inflammation Following Intramuscular Administration of Pseudotyped AAV-TNFR:Fc Vectors in a Rat Model of Arthritis. ASGT meeting 2006.

M. Talba Jr., H.H. Huffer, C.H. Shelburne, J.M. Kriegel, S.A. Goldstein, **K.H. Lustig**, H. Burstein, W.V. Giannobile. Gene Delivery of TNFR:Fc by Adeno-Associated Virus Vector Blocks Progression of Periodontitis. *Molecular Therapy* 11, S262, 2005

D. Zhu, **K.H. Lustig**, K. Bifulco, J. Keifer. Thalamocortical connections in the pond turtle *Pseudemys scripta elegans*. *Brain Behav Evol.* 65(4):278-92, 2005.

Kurt H. Lustig

Z. Sandalon, **K.H. Lustig**, H. Burstein. Long-Term Expression of Soluble TNFR:Fc Protein Following Multiple Administrations of AAV-TNFR:Fc Vector Pseudotyped with Capsids of Alternate Serotypes. ASGT meeting 2004.

Z. Sandalon, **K.H. Lustig**, H. Burstein. Suppression of Inflammation in a Rat model of Arthritis Following Intramuscular Administration of AAV-TNFR:Fc Vector Pseudotyped with AAV type 1 Capsid. ASGT meeting 2004.

Z. Sandalon, E.M. Bruckheimer, **K.H. Lustig**, L.C. Rogers, R.W. Peluso, H. Burstein. Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. *J Virol.* 78(22): 12355-65, 2004.

K.H. Lustig, D. Martin, E.J. Kelly, C. Lynch, R. Peluso, H. Burstein. Long Term Expression of Human Factor IX Following Gene Transfer to the Lungs Utilizing AAV Vector Serotypes 2 and 5. ASGT meeting 2003.

E.J. Kelly, D.R. Jacobson, S.L. Dekker, S.G. Godwin, M. Lippa, **K.H. Lustig**, L. Rogers, Z. Sandalon, T. Stepan, S.A. Thompson, H. Burstein, R.W. Peluso, C.M. Lynch. Transcriptional Activity of Recombinant AAV-FVIII Vectors for Gene Therapy of Hemophilia A. ASGT meeting 2003.

Faquin L., M.R. McNelis, **K. Lustig**, A.M. Gerdes. Hyperplasia and hypertrophy of chicken cardiac myocytes during posthatching development. *Am J. Physiol.* 273: R518-R526, 1997.

K.H. Lustig, A.M. Gerdes, J.M. Capasso. Characterization of enzymatically isolated myocytes from the turtles, *Chrysemys Picta*. *Comp. Biochem. Physiol.* 115B: 475-464, 1996.

- **References upon request**

Seattle Fire Code Advisory Board

15 Members: Pursuant to Ordinance 124707, all members subject to City Council confirmation, 3-year terms:

- 15 Mayor- appointed

Roster:

*D	**G	RD	Position No.	Position Title	Name	Term Begin Date	Term End Date	Term #	Appointed By
6	M		1.	Architect	James R. Fair	4/1/18	3/31/21	4	Mayor
6	F		2.	Chemical Engineer	Tara Henriksen	9/1/18	8/31/21	3	Mayor
6	F		3.	Mechanical Engineer	Rae Anne Rushing	4/1/18	3/31/21	5	Mayor
6	M		4.	BOMA Insurance Industry	Brad Middleton	6/1/19	5/31/22	2	Mayor
			5.						Mayor
1	F		6.	Marine Industry	Amy Liu	9/24/18	9/23/21	1	Mayor
6	M		7.	Port of Seattle	Chris Todd	8/15/17	8/14/20	1	Mayor
6	M		8.	Manufacturing/ Warehouse	Fritz Chess	6/1/19	5/31/22	2	Mayor
6	M		9.	Research Labs	Kurt Lustig	6/1/19	5/31/22	2	Mayor
6	M		10.	Fire Protection Industry	Kevin Marr	8/15/17	8/14/20	1	Mayor
			11.	Public					Mayor
			12.	Public					Mayor
6	M		13.	Labor Major Institutions	Scott Peterson	5/27/17	5/26/20	2	Mayor
3	M		14.		Hugo Sotelo	6/1/19	5/31/22	12	Mayor
2	F		15.	Services Industry	Carlene M. Comrie	5/15/17	5/14/20	1	Mayor

SELF-IDENTIFIED DIVERSITY CHART

			(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)		
	Male	Female	Transgender	NB/ O/ U	Asian	Black/ African American	Hispanic/ Latino	American Indian/ Alaska Native	Other	Caucasian/ Non-Hispanic	Pacific Islander	Middle Eastern	Multiracial
Mayor	8	4			1	1	1			9			
Council													
Other													
Total	8	4			1	1	1			9			

Key:

*D List the corresponding *Diversity Chart* number (1 through 9)

**G List *gender*, M= Male, F= Female, T= Transgender, NB= Non-Binary, O= Other, U= Unknown

RD Residential Council District number 1 through 7 or N/A

Diversity information is self-identified and is voluntary.